Request for Information (RFI) From Non-Federal Stakeholders: Developing the 2020 National Vaccine Plan, 50050-50051 [2019-20415]
Download as PDF
50050
Federal Register / Vol. 84, No. 185 / Tuesday, September 24, 2019 / Notices
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
FDA’s website at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before coming to the meeting.
khammond on DSKJM1Z7X2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Agenda: The committee will discuss
supplemental new drug application
(sNDA 021945/S–023#) for MAKENA
(hydroxyprogesterone caproate
injection, 250 milligrams per milliliter)
manufactured by AMAG
Pharmaceuticals. In 2011, MAKENA
received approval under the accelerated
approval pathway (21 CFR part 314,
subpart H, and section 506(c) of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 356(c)) for reducing the risk
of preterm birth in women with a
singleton pregnancy who have a history
of singleton spontaneous preterm birth.
MAKENA was shown in the
preapproval clinical trial to reduce the
proportion of women who delivered at
less than 37 weeks gestation, a surrogate
endpoint that FDA determined was
reasonably likely to predict a clinical
benefit of preterm birth prevention,
such as improved neonatal mortality
and morbidity. As required under 21
CFR 314.510, the Applicant conducted
a postapproval confirmatory clinical
trial to verify and describe clinical
benefit. AMAG Pharmaceuticals has
disclosed that this completed
confirmatory trial did not demonstrate a
statistically significant difference
between the treatment and placebo arms
for the co-primary endpoints of
reducing the risk of recurrent preterm
birth or improving neonatal mortality
and morbidity. The committee will
consider the trial’s findings and the
sNDA in the context of AMAG
Pharmaceuticals’ confirmatory study
obligation.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s website after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
VerDate Sep<11>2014
17:37 Sep 23, 2019
Jkt 247001
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. All electronic and
written submissions submitted to the
Docket (see ADDRESSES) on or before
October 15, 2019, will be provided to
the committee. Oral presentations from
the public will be scheduled between
approximately 1 p.m. and 2 p.m. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before October 4, 2019. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by October 7, 2019.
Persons attending FDA’s advisory
committee meetings are advised that
FDA is not responsible for providing
access to electrical outlets.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Kalyani Bhatt
(see FOR FURTHER INFORMATION CONTACT)
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at:
https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for
procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: September 17, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–20656 Filed 9–23–19; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Request for Information (RFI) From
Non-Federal Stakeholders: Developing
the 2020 National Vaccine Plan
Office of Infectious Disease and
HIV/AIDS Policy (OIDP), Office of the
Assistant Secretary for Health, Office of
the Secretary, Department of Health and
Human Services (HHS).
ACTION: Notice.
AGENCY:
The development of a
National Vaccine Plan (NVP) was
mandated by Congress as a mechanism
for the Director of the National Vaccine
Program (as delegated by the Assistant
Secretary for Health) to communicate
priorities for achieving the Program’s
responsibilities of ensuring adequate
supply of and access to vaccines and
ensuring the effective and optimal use
of vaccines. The most recent NVP,
released in 2010, provided a
comprehensive 10-year national strategy
for enhancing all aspects of the plan,
including vaccine research and
development, supply, financing,
distribution, and safety; informed
decision-making by consumers and
health care providers; vaccinepreventable disease surveillance;
vaccine effectiveness and use
monitoring; and global cooperation
(https://www.hhs.gov/nvpo/vacc_plan/
index.html). To help inform the
development of the National Vaccine
Plan 2020, HHS is issuing a Request for
Information (RFI). The RFI will solicit
specific information regarding the
priorities, goals, and objectives in the
next iteration of the NVP, remaining
gaps, and stakeholder perspectives for
the 2020–2025 timeframe.
DATES: To be considered, comments
must be received electronically at the
email address provided below, no later
than 5:00 p.m. ET on October 24, 2019.
ADDRESSES: Responses must be
submitted electronically, and should be
addressed to NVP.RFI@hhs.gov. Mailed
paper submissions and submissions
received after the deadline will not be
reviewed.
SUPPLEMENTARY INFORMATION: With U.S.
vaccination rates above 90% for many
childhood vaccines, most individuals
have not witnessed firsthand the
devastating illnesses against which
vaccines offer protection, such as polio
or diphtheria. According to a recent
study, routine childhood immunizations
among U.S. children born in 2009 will
prevent 20 million cases of disease and
42,000 premature deaths, with a net
savings of $13.5 billion in direct costs
SUMMARY:
E:\FR\FM\24SEN1.SGM
24SEN1
Federal Register / Vol. 84, No. 185 / Tuesday, September 24, 2019 / Notices
and $68.8 billion in total societal costs.1
In contrast, adult vaccination coverage
rates have remained persistently low,
with only modest gains for certain
populations in the past few years.2 As
a result, the standards for adult
immunization practice were updated in
2014 to promote integration of vaccines
into routine clinical care for adults.3
Despite the widespread availability of
effective vaccines, vaccine-preventable
diseases (VPDs) remain a significant
public health challenge. In particular,
rates of non-medical exemptions for
childhood vaccines are increasing,4 and
there have been recent measles
outbreaks in the U.S.5 and globally, due
to growing vaccine hesitancy and
coverage levels below the threshold
needed for herd immunity. With an
estimated cost of $20,000 per case of
measles to the public sector in 2016,6
the economic consequences of this and
other VPDs, as well as the health
consequences, are significant.
Furthermore, few adults in any age
group are fully vaccinated as
recommended by the Advisory
Committee on Immunization Practices.
Large disparities in vaccine coverage by
race/ethnicity persist, with African
Americans, Hispanics, and Asian
Americans lagging behind whites in
nearly all vaccination coverage rates.7
VPDs such as pertussis and hepatitis B
continue to take a heavy toll on public
health,8 with 18,975 cases of pertussis
and 3,409 (22,000 estimated) cases of
hepatitis B infections reported in the
United States in 2017.9 10 In light of
khammond on DSKJM1Z7X2PROD with NOTICES
1 Zhou
F et al. Economic evaluation of the routine
childhood immunization program in the United
States, 2009. Pediatrics. 2014; 133: 1–9.
2 https://www.cdc.gov/vaccines/imz-managers/
coverage/adultvaxview/pubs-resources/NHIS2017.html.
3 National Vaccine Advisory Committee.
Recommendations from the National Vaccine
Advisory Committee: standards for adult
immunization practice. Public Health Rep.
2014;129:115–23.
4 Omer, S. et al. Nonmedical exemptions to
school immunization requirements: secular trends
and association of state policies with pertussis
incidence. JAMA. 2006;296(14):1757–1763.
5 https://www.cdc.gov/measles/casesoutbreaks.html.
6 Lo NC, Hotez PJ. Public Health and Economic
Consequences of Vaccine Hesitancy for Measles in
the United States. JAMA Pediatr. 2017;171(9):887–
892. doi:10.1001/jamapediatrics.2017.1695.
7 Lu PJ et al. Racial and Ethnic Disparities in
Vaccination Coverage Among Adult Populations in
the U.S. Am J Prev Med. 2015;49(6 Suppl 4):S412–
S425. doi:10.1016/j.amepre.2015.03.005.
8 https://www.cdc.gov/vaccines/pubs/pinkbook/
downloads/appendices/e/reported-cases.pdf.
9 https://www.chop.edu/centers-programs/
vaccine-education-center/global-immunization/
diseases-and-vaccines-world-view.
10 Schillie et al. Prevention of Hepatitis B Virus
Infection in the United States: Recommendations of
the Advisory Committee on Immunization
Practices. MMWR. 2018;67(1):1–31.
VerDate Sep<11>2014
18:34 Sep 23, 2019
Jkt 247001
these challenges, strengthening the
vaccine and immunization enterprise is
a priority for HHS.
The 2010 National Vaccine Plan
(https://www.hhs.gov/sites/default/files/
nvpo/vacc_plan/2010-Plan/
nationalvaccineplan.pdf) and the
associated implementation plan (https://
www.hhs.gov/sites/default/files/nvpo/
vacc_plan/2010-2015-Plan/
implementationplan.pdf) have played
an important role in guiding strategies
and allocations of resources with
respect to vaccines and vaccination.
However, since the publication of the
2010 National Vaccine Plan, there have
been many changes in the vaccine
landscape.
To respond to the public health
challenges of VPDs, OIDP in
collaboration with other federal partners
is leading the development of the 2020
National Vaccine Plan. This updated
plan will recommend vaccine strategies
across the lifespan and guide priority
actions for the period 2020–2025. To
develop this plan, HHS, through OIDP,
seeks input from subject matter experts
and nonfederal partners and
stakeholders such as health care
providers, national professional
organizations, health departments,
school administrators, communitybased and faith-based organizations,
manufacturers, researchers, advocates,
and persons affected by VPDs.
This request for information seeks
public input on strengthening and
improving the nation’s response to
VPDs and strategies to address
infectious diseases through vaccination.
The 2020 National Vaccine Program
requests information in five broad areas.
Responders may address one or more of
the areas below:
1. Priorities for the 2020 National
Vaccine Plan during 2020–2025. What
do you recommend as the top priorities
for vaccines and immunizations in the
United States? Why are these priorities
most important to you? [Provide up to
2 pages to answer these questions]
2. What changes should be made to
the 2010 National Vaccine Plan to make
it more current and useful? This could
include changes to the goals, objectives,
strategies, activities, indicators, and
other areas of the plan. Which
components of the 2010 National
Vaccine Plan worked well and should
be maintained? [Provide up to 2 pages
to answer these questions]
3. What are the goals, objectives, and
strategies for each of your top priority
areas? Are there any goals in the current
strategy that should be discarded or
revised? Which ones and why? [Provide
up to 2 pages to answer these questions]
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
50051
4. What indicators can be used to
measure your top priorities and goals?
Are there any indicators in the 2010
National Vaccine Plan or the National
Adult Immunization Plan (https://
www.hhs.gov/sites/default/files/nvpo/
national-adult-immunization-plan/
naip.pdf) that should continue to be
used? If so, which ones, and why?
[Provide up to 2 pages to answer these
questions]
5. Identify which stakeholders you
believe should have responsibility for
enacting the objectives and strategies
listed in the 2020 National Vaccine
Plan, as well as for any new objectives
and strategies you suggest. Specifically
identify roles that you or your
organization might have in the 2020
National Vaccine Plan. [Provide up to 2
pages to answer these questions].
The information received will inform
the development of the 2020 National
Vaccine Plan.
Dated: September 9, 2019.
Tammy R. Beckham,
Director, Office of Infectious Disease and HIV/
AIDS Policy.
[FR Doc. 2019–20415 Filed 9–23–19; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the NIH Clinical Center
Research Hospital Board.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: NIH Clinical
Center Research Hospital Board.
Date: October 18, 2019.
Time: 9:00 a.m. to 2:40 p.m.
Agenda: Discussion of Patient Safety,
Quality Improvement Assessment, and
Medical Research Scholars Program.
Place: National Institutes of Health,
Building 1, Wilson Hall, One Center
Drive, Bethesda, MD 20892.
Contact Person: Gretchen Wood, Staff
Assistant, Office of the Director,
National Institutes of Health, One
Center Drive, Building 1, Bethesda, MD
20892, 301–496–4272, woodgs@nih.gov.
E:\FR\FM\24SEN1.SGM
24SEN1
Agencies
[Federal Register Volume 84, Number 185 (Tuesday, September 24, 2019)]
[Notices]
[Pages 50050-50051]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-20415]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Request for Information (RFI) From Non-Federal Stakeholders:
Developing the 2020 National Vaccine Plan
AGENCY: Office of Infectious Disease and HIV/AIDS Policy (OIDP), Office
of the Assistant Secretary for Health, Office of the Secretary,
Department of Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The development of a National Vaccine Plan (NVP) was mandated
by Congress as a mechanism for the Director of the National Vaccine
Program (as delegated by the Assistant Secretary for Health) to
communicate priorities for achieving the Program's responsibilities of
ensuring adequate supply of and access to vaccines and ensuring the
effective and optimal use of vaccines. The most recent NVP, released in
2010, provided a comprehensive 10-year national strategy for enhancing
all aspects of the plan, including vaccine research and development,
supply, financing, distribution, and safety; informed decision-making
by consumers and health care providers; vaccine-preventable disease
surveillance; vaccine effectiveness and use monitoring; and global
cooperation (https://www.hhs.gov/nvpo/vacc_plan/). To help
inform the development of the National Vaccine Plan 2020, HHS is
issuing a Request for Information (RFI). The RFI will solicit specific
information regarding the priorities, goals, and objectives in the next
iteration of the NVP, remaining gaps, and stakeholder perspectives for
the 2020-2025 timeframe.
DATES: To be considered, comments must be received electronically at
the email address provided below, no later than 5:00 p.m. ET on October
24, 2019.
ADDRESSES: Responses must be submitted electronically, and should be
addressed to [email protected]. Mailed paper submissions and submissions
received after the deadline will not be reviewed.
SUPPLEMENTARY INFORMATION: With U.S. vaccination rates above 90% for
many childhood vaccines, most individuals have not witnessed firsthand
the devastating illnesses against which vaccines offer protection, such
as polio or diphtheria. According to a recent study, routine childhood
immunizations among U.S. children born in 2009 will prevent 20 million
cases of disease and 42,000 premature deaths, with a net savings of
$13.5 billion in direct costs
[[Page 50051]]
and $68.8 billion in total societal costs.\1\ In contrast, adult
vaccination coverage rates have remained persistently low, with only
modest gains for certain populations in the past few years.\2\ As a
result, the standards for adult immunization practice were updated in
2014 to promote integration of vaccines into routine clinical care for
adults.\3\
---------------------------------------------------------------------------
\1\ Zhou F et al. Economic evaluation of the routine childhood
immunization program in the United States, 2009. Pediatrics. 2014;
133: 1-9.
\2\ https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html.
\3\ National Vaccine Advisory Committee. Recommendations from
the National Vaccine Advisory Committee: standards for adult
immunization practice. Public Health Rep. 2014;129:115-23.
---------------------------------------------------------------------------
Despite the widespread availability of effective vaccines, vaccine-
preventable diseases (VPDs) remain a significant public health
challenge. In particular, rates of non-medical exemptions for childhood
vaccines are increasing,\4\ and there have been recent measles
outbreaks in the U.S.\5\ and globally, due to growing vaccine hesitancy
and coverage levels below the threshold needed for herd immunity. With
an estimated cost of $20,000 per case of measles to the public sector
in 2016,\6\ the economic consequences of this and other VPDs, as well
as the health consequences, are significant. Furthermore, few adults in
any age group are fully vaccinated as recommended by the Advisory
Committee on Immunization Practices. Large disparities in vaccine
coverage by race/ethnicity persist, with African Americans, Hispanics,
and Asian Americans lagging behind whites in nearly all vaccination
coverage rates.\7\ VPDs such as pertussis and hepatitis B continue to
take a heavy toll on public health,\8\ with 18,975 cases of pertussis
and 3,409 (22,000 estimated) cases of hepatitis B infections reported
in the United States in 2017.9 10 In light of these
challenges, strengthening the vaccine and immunization enterprise is a
priority for HHS.
---------------------------------------------------------------------------
\4\ Omer, S. et al. Nonmedical exemptions to school immunization
requirements: secular trends and association of state policies with
pertussis incidence. JAMA. 2006;296(14):1757-1763.
\5\ https://www.cdc.gov/measles/cases-outbreaks.html.
\6\ Lo NC, Hotez PJ. Public Health and Economic Consequences of
Vaccine Hesitancy for Measles in the United States. JAMA Pediatr.
2017;171(9):887-892. doi:10.1001/jamapediatrics.2017.1695.
\7\ Lu PJ et al. Racial and Ethnic Disparities in Vaccination
Coverage Among Adult Populations in the U.S. Am J Prev Med.
2015;49(6 Suppl 4):S412-S425. doi:10.1016/j.amepre.2015.03.005.
\8\ https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/e/reported-cases.pdf.
\9\ https://www.chop.edu/centers-programs/vaccine-education-center/global-immunization/diseases-and-vaccines-world-view.
\10\ Schillie et al. Prevention of Hepatitis B Virus Infection
in the United States: Recommendations of the Advisory Committee on
Immunization Practices. MMWR. 2018;67(1):1-31.
---------------------------------------------------------------------------
The 2010 National Vaccine Plan (https://www.hhs.gov/sites/default/files/nvpo/vacc_plan/2010-Plan/nationalvaccineplan.pdf) and the
associated implementation plan (https://www.hhs.gov/sites/default/files/nvpo/vacc_plan/2010-2015-Plan/implementationplan.pdf) have played
an important role in guiding strategies and allocations of resources
with respect to vaccines and vaccination. However, since the
publication of the 2010 National Vaccine Plan, there have been many
changes in the vaccine landscape.
To respond to the public health challenges of VPDs, OIDP in
collaboration with other federal partners is leading the development of
the 2020 National Vaccine Plan. This updated plan will recommend
vaccine strategies across the lifespan and guide priority actions for
the period 2020-2025. To develop this plan, HHS, through OIDP, seeks
input from subject matter experts and nonfederal partners and
stakeholders such as health care providers, national professional
organizations, health departments, school administrators, community-
based and faith-based organizations, manufacturers, researchers,
advocates, and persons affected by VPDs.
This request for information seeks public input on strengthening
and improving the nation's response to VPDs and strategies to address
infectious diseases through vaccination. The 2020 National Vaccine
Program requests information in five broad areas. Responders may
address one or more of the areas below:
1. Priorities for the 2020 National Vaccine Plan during 2020-2025.
What do you recommend as the top priorities for vaccines and
immunizations in the United States? Why are these priorities most
important to you? [Provide up to 2 pages to answer these questions]
2. What changes should be made to the 2010 National Vaccine Plan to
make it more current and useful? This could include changes to the
goals, objectives, strategies, activities, indicators, and other areas
of the plan. Which components of the 2010 National Vaccine Plan worked
well and should be maintained? [Provide up to 2 pages to answer these
questions]
3. What are the goals, objectives, and strategies for each of your
top priority areas? Are there any goals in the current strategy that
should be discarded or revised? Which ones and why? [Provide up to 2
pages to answer these questions]
4. What indicators can be used to measure your top priorities and
goals? Are there any indicators in the 2010 National Vaccine Plan or
the National Adult Immunization Plan (https://www.hhs.gov/sites/default/files/nvpo/national-adult-immunization-plan/naip.pdf) that
should continue to be used? If so, which ones, and why? [Provide up to
2 pages to answer these questions]
5. Identify which stakeholders you believe should have
responsibility for enacting the objectives and strategies listed in the
2020 National Vaccine Plan, as well as for any new objectives and
strategies you suggest. Specifically identify roles that you or your
organization might have in the 2020 National Vaccine Plan. [Provide up
to 2 pages to answer these questions].
The information received will inform the development of the 2020
National Vaccine Plan.
Dated: September 9, 2019.
Tammy R. Beckham,
Director, Office of Infectious Disease and HIV/AIDS Policy.
[FR Doc. 2019-20415 Filed 9-23-19; 8:45 am]
BILLING CODE 4150-28-P